Jorge E Cortes1, Jeffrey H Lipton2, Carole B Miller3, Lambert Busque4, Luke P Akard5, Javier Pinilla-Ibarz6, Christopher Keir7, Ghulam Warsi7, Felice P Lin7, Michael J Mauro8. 1. The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: jcortes@mdanderson.org. 2. Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada. 3. St. Agnes Hospital, Baltimore, MD. 4. University of Montreal, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada. 5. Indiana Blood and Marrow Transplantation, Indianapolis, IN. 6. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. 7. Novartis Pharmaceuticals Corporation, East Hanover, NJ. 8. Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
BACKGROUND: Many patients with chronic myeloid leukemia in chronic phase experience chronic treatment-related adverse events (AEs) during imatinib therapy. These AEs can impair quality of life and lead to reduced treatment adherence, which is associated with poor clinical outcomes. PATIENTS AND METHODS: In the phase II ENRICH (Exploring Nilotinib to Reduce Imatinib Related Chronic Adverse Events) study (N = 52), the effect of switching patients with imatinib-related chronic low-grade nonhematologic AEs from imatinib to nilotinib was evaluated. RESULTS: Three months after switching to nilotinib, 84.6% of the patients had overall improvement in imatinib-related AEs (primary endpoint). Of 210 imatinib-related AEs identified at baseline, 62.9% had resolved within 3 months of switching to nilotinib. Of evaluable patients, most had improvements in overall quality of life after switching to nilotinib. At screening, 65.4% of evaluable patients had a major molecular response (BCR-ABL1 ≤ 0.1% on the International Scale). After switching to nilotinib, the rate of the major molecular response was 76.1% at 3 months and 87.8% at 12 months. Treatment-emergent AEs reported with nilotinib were typically grade 1 or 2; however, some patients developed more serious AEs, and 8 patients discontinued nilotinib because of new or worsening AEs. CONCLUSION: Overall, results from the ENRICH study demonstrated that switching to nilotinib can mitigate imatinib-related chronic low-grade nonhematologic AEs in patients with chronic myeloid leukemia in chronic phase, in conjunction with acceptable safety and achievement of molecular responses. This trial was registered at www.clinicaltrials.gov as NCT00980018.
BACKGROUND: Many patients with chronic myeloid leukemia in chronic phase experience chronic treatment-related adverse events (AEs) during imatinib therapy. These AEs can impair quality of life and lead to reduced treatment adherence, which is associated with poor clinical outcomes. PATIENTS AND METHODS: In the phase II ENRICH (Exploring Nilotinib to Reduce Imatinib Related Chronic Adverse Events) study (N = 52), the effect of switching patients with imatinib-related chronic low-grade nonhematologic AEs from imatinib to nilotinib was evaluated. RESULTS: Three months after switching to nilotinib, 84.6% of the patients had overall improvement in imatinib-related AEs (primary endpoint). Of 210 imatinib-related AEs identified at baseline, 62.9% had resolved within 3 months of switching to nilotinib. Of evaluable patients, most had improvements in overall quality of life after switching to nilotinib. At screening, 65.4% of evaluable patients had a major molecular response (BCR-ABL1 ≤ 0.1% on the International Scale). After switching to nilotinib, the rate of the major molecular response was 76.1% at 3 months and 87.8% at 12 months. Treatment-emergent AEs reported with nilotinib were typically grade 1 or 2; however, some patients developed more serious AEs, and 8 patients discontinued nilotinib because of new or worsening AEs. CONCLUSION: Overall, results from the ENRICH study demonstrated that switching to nilotinib can mitigate imatinib-related chronic low-grade nonhematologic AEs in patients with chronic myeloid leukemia in chronic phase, in conjunction with acceptable safety and achievement of molecular responses. This trial was registered at www.clinicaltrials.gov as NCT00980018.
Authors: Loretta A Williams; Araceli G Garcia Gonzalez; Patricia Ault; Tito R Mendoza; Mary L Sailors; Janet L Williams; Furong Huang; Aziz Nazha; Hagop M Kantarjian; Charles S Cleeland; Jorge E Cortes Journal: Blood Date: 2013-06-18 Impact factor: 22.113
Authors: Amr R Ibrahim; Lina Eliasson; Jane F Apperley; Dragana Milojkovic; Marco Bua; Richard Szydlo; Francois-Xavier Mahon; Kasia Kozlowski; Christos Paliompeis; Letizia Foroni; Jamshid S Khorashad; Alex Bazeos; Mathieu Molimard; Alistair Reid; Katayoun Rezvani; Gareth Gerrard; John Goldman; David Marin Journal: Blood Date: 2011-02-23 Impact factor: 22.113
Authors: Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre Journal: Blood Date: 2010-11-22 Impact factor: 22.113
Authors: Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Annie Guérin; Lei Chen; Raluca Ionescu-Ittu; Maryna Marynchenko; Roy Nitulescu; Robert Hiscock; Christopher Keir; Eric Qiong Wu Journal: Curr Med Res Opin Date: 2014-08-05 Impact factor: 2.580
Authors: F J Giles; P D le Coutre; J Pinilla-Ibarz; R A Larson; N Gattermann; O G Ottmann; A Hochhaus; J P Radich; G Saglio; T P Hughes; G Martinelli; D-W Kim; S Novick; K Gillis; X Fan; J Cortes; M Baccarani; H M Kantarjian Journal: Leukemia Date: 2012-07-05 Impact factor: 11.528
Authors: Timothy P Hughes; Jeffrey H Lipton; Nelson Spector; Francisco Cervantes; Ricardo Pasquini; Nelma Cristina D Clementino; Pedro Enrique Dorlhiac Llacer; Anthony P Schwarer; Francois-Xavier Mahon; Delphine Rea; Susan Branford; Das Purkayastha; LaTonya Collins; Tomasz Szczudlo; Brian Leber Journal: Blood Date: 2014-06-19 Impact factor: 22.113
Authors: Kelly L Schoenbeck; Ehab Atallah; Li Lin; Kevin P Weinfurt; Jorge Cortes; Michael W N Deininger; Vamsi Kota; Richard A Larson; Michael J Mauro; Vivian G Oehler; Javier Pinilla-Ibarz; Jerald P Radich; Charles A Schiffer; Neil P Shah; Richard T Silver; James E Thompson; Kathryn E Flynn Journal: J Natl Cancer Inst Date: 2022-01-11 Impact factor: 11.816